Indaptus Therapeutics
INDP
14 hedge funds and large institutions have $10.5M invested in Indaptus Therapeutics in 2021 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 6 increasing their positions, 0 reducing their positions, and 4 closing their positions.
253% more capital inflows, than outflows
Capital inflows: $11.3M | Capital outflows: $3.2M
15.81% more ownership
Funds ownership: 6.61% → 22.42% (+16%)
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Stratos Wealth Partners
Beachwood,
Ohio
|
+$9.21M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$850K |
| 3 |
Investment House LLC
Redondo Beach,
California
|
+$464K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$388K |
| 5 |
Millennium Management
New York
|
+$252K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Armistice Capital
New York
|
-$2.99M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$111K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$100K |
INDP Hedge Fund Activity: Q4 2021 in Review
14 of the 6,522 institutional investors tracked by Wall St. Rank reported a position in Indaptus Therapeutics (INDP) for Q4 2021, worth a combined $10.5M — up 147% from $4.24M a quarter earlier.
Fund positioning in INDP was balanced in Q4 2021: 4 funds opened new positions, 4 closed out, 6 added to existing stakes and 0 trimmed.
The largest buyer was Stratos Wealth Partners, opening a new position worth an estimated $9.21M. The largest seller was Armistice Capital, exiting entirely with an estimated $2.99M sold.
- 14 institutional investors held Indaptus Therapeutics (INDP) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $10.5M of Indaptus Therapeutics stock for Q4 2021, up 147% quarter-over-quarter.
- 4 funds opened new Indaptus Therapeutics positions in Q4 2021 and 4 closed out, a net change of 0 holders.
- The largest Indaptus Therapeutics buyer in Q4 2021 was Stratos Wealth Partners, an estimated $9.21M added.
- The largest Indaptus Therapeutics seller in Q4 2021 was Armistice Capital, an estimated $2.99M sold.
Based on aggregated 13F filings for Q4 2021.